JP2017537967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537967A5 JP2017537967A5 JP2017532660A JP2017532660A JP2017537967A5 JP 2017537967 A5 JP2017537967 A5 JP 2017537967A5 JP 2017532660 A JP2017532660 A JP 2017532660A JP 2017532660 A JP2017532660 A JP 2017532660A JP 2017537967 A5 JP2017537967 A5 JP 2017537967A5
- Authority
- JP
- Japan
- Prior art keywords
- neuropathy
- damage
- independently
- compound according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 83
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 64
- 201000001119 neuropathy Diseases 0.000 claims description 57
- 230000007823 neuropathy Effects 0.000 claims description 57
- 230000006378 damage Effects 0.000 claims description 36
- 208000028389 Nerve injury Diseases 0.000 claims description 35
- 230000008764 nerve damage Effects 0.000 claims description 35
- 229920006395 saturated elastomer Polymers 0.000 claims description 34
- 210000003169 central nervous system Anatomy 0.000 claims description 28
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 28
- 208000024827 Alzheimer disease Diseases 0.000 claims description 25
- 206010033799 Paralysis Diseases 0.000 claims description 22
- 230000000926 neurological effect Effects 0.000 claims description 22
- 210000001328 optic nerve Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 208000010877 cognitive disease Diseases 0.000 claims description 15
- 208000020431 spinal cord injury Diseases 0.000 claims description 14
- 206010036105 Polyneuropathy Diseases 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 12
- 230000007824 polyneuropathy Effects 0.000 claims description 12
- 230000008733 trauma Effects 0.000 claims description 12
- 201000001881 impotence Diseases 0.000 claims description 10
- 230000001272 neurogenic effect Effects 0.000 claims description 10
- 201000005518 mononeuropathy Diseases 0.000 claims description 9
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 206010065681 HIV peripheral neuropathy Diseases 0.000 claims description 7
- 206010024229 Leprosy Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 206010033892 Paraplegia Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 238000011472 radical prostatectomy Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 230000014511 neuron projection development Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000007074 memory dysfunction Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000002241 neurite Anatomy 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 102000003702 retinoic acid receptors Human genes 0.000 claims 8
- 108090000064 retinoic acid receptors Proteins 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000026139 Memory disease Diseases 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102100033909 Retinoic acid receptor beta Human genes 0.000 description 6
- 108091008761 retinoic acid receptors β Proteins 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 2
- AVCXUODHLRZJJP-UHFFFAOYSA-N 4-[5-(4,7-dimethyl-1-benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound CC1=CC=C(C2=C1C=C(O2)C1=NC(=NO1)C1=CC=C(C(=O)O)C=C1)C AVCXUODHLRZJJP-UHFFFAOYSA-N 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422472 | 2014-12-17 | ||
| GB1422472.9 | 2014-12-17 | ||
| PCT/EP2015/080029 WO2016097004A1 (en) | 2014-12-17 | 2015-12-16 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537967A JP2017537967A (ja) | 2017-12-21 |
| JP2017537967A5 true JP2017537967A5 (https=) | 2019-01-24 |
| JP6596090B2 JP6596090B2 (ja) | 2019-10-23 |
Family
ID=55027725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532660A Active JP6596090B2 (ja) | 2014-12-17 | 2015-12-16 | レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9994559B2 (https=) |
| EP (1) | EP3233842B1 (https=) |
| JP (1) | JP6596090B2 (https=) |
| KR (1) | KR102526625B1 (https=) |
| CN (1) | CN107207488B (https=) |
| AU (1) | AU2015367531B2 (https=) |
| BR (1) | BR112017012588B8 (https=) |
| CA (1) | CA2970574C (https=) |
| ES (1) | ES3029609T3 (https=) |
| IL (1) | IL252882B (https=) |
| WO (1) | WO2016097004A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207488B (zh) | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
| GB201610867D0 (en) * | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| CN111892591A (zh) * | 2019-05-06 | 2020-11-06 | 南京科技职业学院 | 一种维奈托克关键中间体的合成方法 |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| CN115427401B (zh) | 2020-05-29 | 2025-04-11 | 巴斯夫欧洲公司 | 取代4-(n′-羟基甲脒基)苯甲酸的制备 |
| CN112552252B (zh) * | 2020-09-30 | 2024-01-02 | 浙江美诺华药物化学有限公司 | 一种氟雷拉纳中间体的制备方法 |
| CN113264832A (zh) * | 2021-05-13 | 2021-08-17 | 南京爱可德夫科技开发有限公司 | 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法 |
| CN116640071B (zh) * | 2023-05-04 | 2024-08-30 | 四川青木制药有限公司 | 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9802290A3 (en) | 1995-06-07 | 2002-02-28 | Nippon Shinyaku Co Ltd | Pyrrole derivatives and pharmaceutical compositions containing them |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| KR100485642B1 (ko) | 1996-03-18 | 2005-09-30 | 에자이 가부시키가이샤 | 축합고리함유카르복실산유도체 |
| JPH10158192A (ja) | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物 |
| GB9907461D0 (en) | 1999-03-31 | 1999-05-26 | King S College London | Neurite regeneration |
| JP2000154150A (ja) * | 1997-10-22 | 2000-06-06 | Eisai Co Ltd | 腎炎予防・治療剤としてのレチノイン酸アゴニスト |
| CA2307613A1 (en) | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis |
| US6809107B1 (en) * | 1999-07-09 | 2004-10-26 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| US20020048580A1 (en) * | 2000-06-07 | 2002-04-25 | Institut National De La Sante Et De La Recherche Medicale | Method of inducing lung branching |
| KR20040004705A (ko) | 2001-06-08 | 2004-01-13 | 시토비아 인크. | 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도 |
| JP2003081832A (ja) | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| WO2003062230A1 (en) * | 2002-01-21 | 2003-07-31 | Eisai Co., Ltd. | Conbinatorial library of heterocycle compounds |
| IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| EP4101846B1 (en) * | 2003-04-11 | 2023-08-02 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| EP1799659A1 (en) * | 2004-10-13 | 2007-06-27 | PTC Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| CN102047061A (zh) | 2008-05-30 | 2011-05-04 | 福斯特韦勒能源股份公司 | 通过氧化燃料燃烧发电的方法和系统 |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| GB0915196D0 (en) * | 2009-09-01 | 2009-10-07 | King S College London | Therapeutic compounds and their use |
| US20120289476A1 (en) | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN107207488B (zh) * | 2014-12-17 | 2020-11-17 | 伦敦皇家学院 | 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物 |
-
2015
- 2015-12-16 CN CN201580073462.9A patent/CN107207488B/zh active Active
- 2015-12-16 EP EP15817206.4A patent/EP3233842B1/en active Active
- 2015-12-16 AU AU2015367531A patent/AU2015367531B2/en active Active
- 2015-12-16 WO PCT/EP2015/080029 patent/WO2016097004A1/en not_active Ceased
- 2015-12-16 KR KR1020177019558A patent/KR102526625B1/ko active Active
- 2015-12-16 CA CA2970574A patent/CA2970574C/en active Active
- 2015-12-16 BR BR112017012588A patent/BR112017012588B8/pt active IP Right Grant
- 2015-12-16 US US15/533,492 patent/US9994559B2/en active Active
- 2015-12-16 JP JP2017532660A patent/JP6596090B2/ja active Active
- 2015-12-16 ES ES15817206T patent/ES3029609T3/es active Active
-
2017
- 2017-06-13 IL IL252882A patent/IL252882B/en active IP Right Grant
-
2018
- 2018-06-05 US US15/997,796 patent/US10385044B2/en active Active
-
2019
- 2019-08-09 US US16/536,441 patent/US10752616B2/en active Active
-
2020
- 2020-08-19 US US16/997,855 patent/US11401265B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537967A5 (https=) | ||
| JP7579402B2 (ja) | 癌治療用ｐｔｐｎ１１（ｓｈｐ２）阻害剤としての６－（４－アミノ－３－メチル－２－オキサ－８－アザスピロ［４．５］デカン－８－イル）－３－（２，３－ジクロロフェニル）－２－メチルピリミジン－４（３ｈ）－オン誘導体及び関連化合物 | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| JP2019535723A5 (https=) | ||
| CA2981499A1 (en) | Methods of administering glutaminase inhibitors | |
| JP2019532079A5 (https=) | ||
| JP2019500377A (ja) | がん及び炎症性疾患の処置のための化合物 | |
| JP2021105002A5 (https=) | ||
| EA200901162A1 (ru) | Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2 | |
| JP2013502430A5 (https=) | ||
| EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
| EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
| JP2013500314A5 (https=) | ||
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| BR0207390A (pt) | Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur | |
| JP2017524005A5 (https=) | ||
| JP2013536833A5 (https=) | ||
| JP2020502092A5 (https=) | ||
| JP2020527173A5 (https=) | ||
| JP2006507220A5 (https=) | ||
| DE602005016261D1 (de) | Substituierte arylaminderivate und verwendungsverfahren | |
| JP2017524733A5 (https=) | ||
| JP2015508092A5 (https=) | ||
| RU2016151420A (ru) | Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий | |
| JPH06511251A (ja) | ヒスタミンｈ↓３アゴニスト／アンタゴニストとしてのイミダゾリル−アルキル−ピペラジンおよび−ジアゼピン誘導体 |